Intestinal glucagon-like peptide-1 in hypoglycemic counterregulation for type 1 diabetes management  

作　　者：Ke-Xin Zhang Cheng-Xia Kan Yu-Qun Wang Ning-Ning Hou Xiao-Dong Sun 

机构地区：[1]Department of Endocrinology and Metabolism,The Affiliated Hospital of Shandong Second Medical University,Weifang 261031,Shandong Province,China

出　　处：《World Journal of Diabetes》2024年第12期2380-2383,共4页世界糖尿病杂志（英文）

摘　　要：Type 1 diabetes(T1D)is characterized by the autoimmune destruction of pan-creatic beta cells,leading to absolute insulin deficiency and the need for exoge-nous insulin.A significant concern in T1D management is hypoglycemia,which is worsened by impaired counterregulatory mechanisms.Effective counterregu-lation involves hormones such as glucagon and adrenaline,which work to restore normal blood glucose levels.However,in T1D,these mechanisms often fail,par-ticularly after recurrent hypoglycemia,resulting in hypoglycemia-associated au-tonomic failure.Recent research indicates that elevated levels of intestinal glu-cagon-like peptide-1(GLP-1)impair counterregulatory responses by reducing the secretion of glucagon and adrenaline.This editorial underscores GLP-1’s role be-yond its incretin effects,contributing to impaired hypoglycemic counterregu-lation.This understanding necessitates a nuanced approach to GLP-1-based the-rapies in T1D,balancing the benefits of glycemic control with potential risks.Future research should delve into the mechanisms behind GLP-1’s effects and explore potential interventions to improve hypoglycemic counterregulation.The goal is to enhance the safety and quality of life for T1D patients.

关 键 词：Type 1 diabetes Glucagon-like peptide-1 HYPOGLYCEMIA Hypoglycemic counterregulation Hormonal reaction 

分 类 号：R587.2[医药卫生—内分泌] R692.9[医药卫生—内科学]